Novozymes A/S (NVZMF)
| Previous close | 57.94 |
| Open | 58.75 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 58.75 - 58.75 |
| 52-week range | 38.16 - 82.30 |
| Volume | |
| Avg. volume | 1,320 |
| Market cap | 16.703B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 33.96 |
| EPS (TTM) | 1.73 |
| Earnings date | N/A |
| Forward dividend & yield | 0.82 (1.41%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Globe Newswire
As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative
Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero. COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to S
- Globe Newswire
Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth
COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes’ human healt
- Globe Newswire
Novozymes confirms upgraded guidance by strong start to Q4
Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum. COPENHAGEN, Denmark – November 3, 2022. In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin o
